It's possible to reverse the process and identify new therapeutic pathways
En los laboratorios de la Universidad Miguel Hernández de España, un equipo de investigadores ha identificado una molécula experimental llamada OLE que parece despertar las defensas inmunitarias del cerebro frente al Alzheimer, reprogramando las células encargadas de limpiar los depósitos tóxicos para que recuperen su capacidad protectora. Este hallazgo, publicado en una revista científica de referencia y respaldado por dos patentes europeas, no busca atacar la enfermedad desde fuera, sino restaurar los mecanismos que el propio cerebro posee para defenderse. En un mundo donde el Alzheimer sigue siendo una de las grandes incógnitas de la medicina, este avance sugiere que la respuesta podría residir, en parte, en reactivar lo que la enfermedad ha silenciado.
- El Alzheimer no solo destruye neuronas: también desactiva las células inmunitarias del cerebro que deberían protegerlas, convirtiendo a los aliados en parte del problema.
- La molécula OLE, derivada del gen PM20D1, actúa como un reinicio celular que devuelve a las microglías su capacidad de rodear y contener las placas de amiloide antes de que dañen las neuronas.
- En ratones tratados durante tres meses, los resultados fueron contundentes: mejor rendimiento en pruebas de memoria y una reducción visible de las placas amiloides asociadas a la enfermedad.
- El análisis de miles de células cerebrales individuales reveló que las microglías tratadas con OLE recuperaban su movilidad y su capacidad de migrar hacia los depósitos tóxicos para eliminarlos.
- Dos patentes europeas ya protegen los hallazgos, y el respaldo de instituciones como el Consejo Europeo de Investigación apunta a que este camino tiene futuro terapéutico real.
En el campus de Sant Joan d'Alacant de la Universidad Miguel Hernández, un equipo liderado por José Vicente Sánchez Mut ha dado con una molécula que podría cambiar el enfoque en la lucha contra el Alzheimer. La sustancia, denominada OLE y derivada del gen PM20D1, no ataca la enfermedad directamente, sino que reprograma las microglías —las células inmunitarias del cerebro— para que recuperen su función natural: limpiar los depósitos tóxicos de proteína amiloide que caracterizan la enfermedad.
A medida que el Alzheimer avanza, las microglías pierden su capacidad protectora e incluso pueden contribuir al daño neuronal. OLE parece revertir este proceso, empujando a estas células de vuelta a un estado activo en el que rodean las placas, forman una barrera y limitan su interacción tóxica con las neuronas. Los experimentos comenzaron con gusanos modificados genéticamente para producir beta-amiloide: el tratamiento redujo la acumulación de agregados tóxicos y mejoró su movilidad. Posteriormente, ratones con patología similar al Alzheimer recibieron el compuesto durante tres meses, con resultados notables en pruebas de memoria y una reducción visible de las placas en el cerebro.
La investigadora Victoria Pozzi, autora principal del estudio, analizó la actividad de miles de células cerebrales individuales y comprobó que las microglías eran las que respondían de forma más dramática al tratamiento. En cultivos de laboratorio, estas células mostraron mayor capacidad para migrar hacia los depósitos amiloides y promover su eliminación. Además, cuando las neuronas fueron expuestas a condiciones que simulaban el estrés del Alzheimer, el tratamiento con OLE aumentó su supervivencia, lo que sugiere que la molécula también protege directamente a las células nerviosas.
El trabajo, publicado en Cell Death and Disease y desarrollado en colaboración con Johannes Gräf del Instituto Federal Suizo de Tecnología de Lausana, está respaldado por dos patentes europeas —una de ellas en manos del CSIC— y financiado por fuentes internacionales que incluyen el Consejo Europeo de Investigación y el Ministerio de Ciencia e Innovación de España. Para Sánchez Mut, el mensaje central es claro: el cerebro tiene mecanismos de defensa que el Alzheimer silencia, y OLE demuestra que ese silencio puede romperse.
In a laboratory at Spain's Miguel Hernández University, researchers have identified a molecule that appears to wake up the brain's immune system and help it fight back against Alzheimer's disease. The compound, called OLE, works by reprogramming microglia—the immune cells responsible for cleaning toxic deposits from brain tissue—and restoring their ability to contain and reduce the damage caused by amyloid plaques, the hallmark protein accumulations that characterize the disease.
José Vicente Sánchez Mut, who leads the Functional Epigenomics of Aging and Alzheimer's Disease laboratory at the university's Sant Joan d'Alacant campus, collaborated with Johannes Gräf from Switzerland's École Polytechnique Fédérale de Lausanne to conduct the research. Their findings, published in Cell Death and Disease, demonstrate that OLE is derived from the PM20D1 gene and acts as a kind of cellular reset button. When microglia encounter amyloid plaques in the brain, they normally work to clear them away. But as Alzheimer's progresses, these cells lose their protective capacity and can even contribute to neuronal damage. OLE appears to reverse this decline, pushing microglia back into a healthier state where they actively surround the plaques, forming a barrier that limits their toxic interaction with neurons.
To test the molecule's effects, the research team employed a methodical approach across multiple experimental systems. They began with genetically modified roundworms engineered to produce beta-amyloid, which allowed for rapid assessment of toxicity. In these organisms, OLE treatment reduced the buildup of toxic aggregates and improved mobility—a sign of protection against disease-related damage. The team then administered the compound to mice with Alzheimer's-like pathology for three months. The results were striking: treated animals performed better on memory tests and showed reduced amyloid plaques in their brains.
To understand exactly how OLE worked at the cellular level, the researchers analyzed the activity of thousands of individual brain cells. Victoria Pozzi, the study's lead author, found that microglia responded most dramatically to the treatment. The cells activated mechanisms related to clearing amyloid and regained their mobility—their ability to move toward the plaques and contain them. In laboratory cultures, microglia treated with OLE showed enhanced capacity to migrate toward amyloid deposits and promote their removal. When neurons were exposed to stress conditions mimicking Alzheimer's disease, OLE treatment increased their survival, suggesting the molecule also provides direct protection to nerve cells themselves.
The implications of this work extend beyond the laboratory. The findings are protected by two European patents, one held by Spain's National Research Council (CSIC), signaling that the research team and their institutions view the molecule as having genuine therapeutic potential. Sánchez Mut emphasized the significance of their discovery: in Alzheimer's disease, microglia stop functioning properly, but the team's work demonstrates that this process can be reversed. The research opens new pathways for understanding how to fight the disease and points toward possible treatments that could restore the brain's natural defense mechanisms rather than simply attacking the disease from outside. The work was supported by funding from multiple international sources, including Swiss foundations, the European Research Council, and Spain's Ministry of Science and Innovation, reflecting the collaborative and well-resourced nature of the effort.
Notable Quotes
In Alzheimer's disease, these cells stop functioning correctly. Our results show it's possible to reverse the process and identify new therapeutic pathways to fight the disease.— José Vicente Sánchez Mut, lead researcher
The analysis of individual cells allowed us to confirm that microglia was the cell type that responded most strongly to the treatment, helping it move toward amyloid plaques and better contain the damage.— Victoria Pozzi, first author of the study
The Hearth Conversation Another angle on the story
Why does it matter that you're working with microglia specifically, rather than trying to attack the plaques directly?
Because the plaques are a symptom, not the root problem. The brain has its own cleanup crew—microglia—but in Alzheimer's, these cells get tired or confused. They stop doing their job. We're not trying to replace them or fight the disease from outside. We're trying to remind them how to work again.
And this OLE molecule—where does it come from? Is it something you synthesized, or did you find it in nature?
It's derived from a gene called PM20D1. So it's not entirely synthetic, but it's not something you'd find in a pill bottle either. It's a molecular signal that tells microglia to wake up and behave the way they should.
You tested it in worms first, then mice. Why that progression?
Worms are fast. You can see toxicity effects quickly, and they're simple enough that you can isolate what's happening. Mice are closer to humans—their brains work more like ours do. Three months of treatment in a mouse is a meaningful timeframe to see if memory actually improves.
The mice showed better memory after treatment. But is that because the plaques were gone, or because the neurons were protected, or both?
Both, probably. The plaques got smaller and less toxic. But we also saw that OLE protected neurons directly when they were under stress. So it's working on multiple fronts—cleaning up the mess and shielding the cells from damage.
What happens next? When do people get to try this?
That's the honest answer: we don't know yet. We have patents, which means the work is protected and there's a path toward development. But moving from mice to humans is a long journey. We've shown the principle works. Now comes the harder part—making sure it's safe and effective in people.